Best Net Payout Yield Companies To Own For 2014

Advisors are falling behind in helping their aging clients prepare for what could likely be one of their most costly expenses in retirement: where to live, according to a just-released study by Legg Mason.

Legg Mason recently collaborated with the Center for Innovative Care in Aging at the Johns Hopkins School of Nursing to create a new Planning for Housing advisor education program.

A new survey of 506 financial advisors by Legg Mason found that only 14% of advisors have helped their clients develop specific plans to address their future long-term housing needs, such as downsizing, moving to a retirement community or preparing for advanced care. This lack of focus on their clients’ housing needs in retirement comes despite the fact that nearly half of the advisors surveyed (45%) said they have “personally considered other housing options” for their own retirement.

The advisors polled said that the primary reason they have not helped their clients plan for their housing in retirement is because “My clients do not ask about it,” while 26% of the advisors who have not helped clients plan for housing in retirement said they do not feel “knowledgeable enough about the topic” to address it.

Top Railroad Companies To Invest In 2015: Imperial Holdings Inc. (IFT)

Imperial Holdings, Inc., through its subsidiaries, operates as a specialty finance company in the United States. The company operates in two business segments: Life Finance and Structured Settlements. The Life Finance segment comprises life settlements and finance loan businesses. The Structured Settlement segment purchases structured settlements at a discounted rate and sells such assets to third parties. This segment primarily markets its products through the Internet and television. Imperial Holdings, Inc. was founded in 2006 and is based in Boca Raton, Florida.

Advisors' Opinion:

• [By Whopper Investments]

  Note: This is my response to the recent short case on Imperial Finance (IFT). Obviously, all humans are fallible, and I'm sure someone can find just as much to argue with my long case as I found to argue with his short case. Please read for yourself, do your own research, and make your own decision. I am long IFT and plan on fully participating in the rights offering.

• [By DCResearch]

  Imperial Holdings (IFT) fits the bill for all of those traits and investors today can buy Imperial Holdings for less than 0.75x book value. Upside to book value, an obvious valuation factor for most financial companies, would result in a greater than 40% return for a patient investor. I believe that this is far below the fair value for IFT�� book of life settlements, and upside is in excess of $13 per share.

Best Net Payout Yield Companies To Own For 2014: ARIAD Pharmaceuticals Inc.(ARIA)

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company?s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and non-small cell lung cancer. Its product pipeline also includes ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. In addition, the company focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. Further, it licenses its ARGENT cell-sign aling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products, and to conduct drug discovery research. The company has collaboration and license agreements with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent restenosis of injured vessels. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Jason Shubnell]

  Ariad Pharmaceuticals (NASDAQ: ARIA) was also up, gaining 7.43 percent to $8.16 on a report from the UK Daily Mail that Jazz Pharmaceuticals is willing to pay $20.00 per share for the maker of Iclusig.

• [By Brian Orelli]

  Investment opportunity in expanding indications
  Ariad Pharmaceuticals (NASDAQ: ARIA  ) gained FDA approval for its leukemia drug Iclusig�at the end of last year and managed $6.4 million in sales in the first quarter. That's a pretty decent start, and the drug should be launched in Europe next month, accelerating sales further.

• [By Brian Orelli]

  ARIAD Pharmaceuticals (NASDAQ: ARIA  ) , for instance, fell more than 20% after receiving FDA approval for its leukemia drug Iclusig. ARIAD had more than doubled from the year before as it ran up to the decision. Shares still haven't recovered to their pre-run-up level. Binary event traders have moved on. To add to its $3.6 billion valuation from here, ARIAD is going to have to do it the old-fashioned way: increasing sales.

• [By Jake L'Ecuyer]

  Top Headline
  Procter & Gamble Co (NYSE: PG) reported a better-than-expected second-quarter net profit. Procter & Gamble's quarterly profit declined to $3.43 billion, or $1.18 per share, from a year-ago profit of $4.06 billion, or $1.39 per share. Its core earnings fell to $1.21 per share. Its sales came in at $22.28 billion versus $22.18 billion. However, analysts were projecting earnings of $1.20 per share on sales of $22.36 billion. Equities Trading UP
  Juniper Networks (NYSE: JNPR) shot up 7.04 percent to $27.85 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00. Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) were up as well, gaining a staggering 21.68 percent to $9.14 as rumours of a takeover from a major pharma name swirled around the street. Microsoft (NASDAQ: MSFT) was also up, gaining 2.66 percent to $37.01 after the company reported stronger-than-expected fiscal second-quarter results. Credit Suisse raised the price target on the stock from $40.00 to $42.50.

Best Net Payout Yield Companies To Own For 2014: Tortoise Pipeline & Energy Fund Inc (TTP)

Tortoise Pipeline & Energy Fund, Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund�� investment objective is to provide a high level of total return. It focuses to provide stockholders a vehicle to invest in a portfolio consisting of equity securities of pipeline and other energy infrastructure companies. It focuses on pipeline companies, which are engaged in the business of transporting natural gas, natural gas liquids (NGLs), crude oil and refined petroleum products, and on other energy infrastructure companies. It focus invest at least 80% of its total assets in equity securities of pipeline and other energy infrastructure companies. It may invest up to 30% of its total assets in unregistered or otherwise restricted securities, primarily through direct investments in securities of listed companies. Tortoise Capital Advisors, L.L.C. serves as the Fund�� investment adviser. Advisors' Opinion:

• [By Robert Rapier]

  As I write this, Tortoise Pipeline and Energy (NYSE: TTP) trades at a discount of 15.1 percent to its underlying assets, while at the other end of the spectrum Cushing MLP Total Return Fund (NYSE: SRV) trades at a 17.4 percent premium. The average MLP closed-end fund listed trades at a 4.9 percent discount, which is perhaps reasonable given the loss of certain tax advantages and the fact that management fees will eat into returns.

• [By Robert Rapier]

  As I write this, Tortoise Pipeline and Energy (NYSE: TTP) trades at a discount of 15.1 percent to its underlying assets, while at the other end of the spectrum Cushing MLP Total Return Fund (NYSE: SRV) trades at a 17.4 percent premium. The average MLP closed-end fund listed trades at a 4.9 percent discount, which is perhaps reasonable given the loss of certain tax advantages and the fact that management fees will eat into returns.

Best Net Payout Yield Companies To Own For 2014: Rackspace Hosting Inc(RAX)

Rackspace Hosting, Inc. operates in the hosting and cloud computing industry. It provides information technology (IT) as a service, managing Web-based IT systems for small and medium-sized businesses, as well as large enterprises worldwide. The company?s service suite includes dedicated hosting comprising customer management portal and other management tools that manage data center, network, hardware devices, and operating system software; and cloud computing that enables customers to provide and manage a pool of computing resources, as well as delivery of computing resources to business when they need them. It offers cloud servers, cloud files, and cloud sites, as well as cloud applications, such as email, collaboration, and file back-ups; and hybrid hosting that provides a combination of dedicated hosting and cloud computing services. The company also offers customer support services. It sells its service suite through direct sales teams, third-party channel partners, an d online ordering. The company was formerly known as Rackspace.com, Inc. and changed its name to Rackspace Hosting, Inc. in June 2008. Rackspace Hosting, Inc. was founded in 1998 and is headquartered in San Antonio, Texas.

Advisors' Opinion:

• [By Jayson Derrick]

  Rackspace Hosting (NYSE: RAX) plans to offer two services tiers. The first would be a basic managed infrastructure tier that provides standard laaS services. The second would be a managed operations tier that includes a dedicated account manager, 24-hours-a-day, seven-days-a-week monitoring and response, and management of common operating systems and application stacks. Shares lost 1.43 percent, closing at $31.69.

Best Net Payout Yield Companies To Own For 2014: Mylan Inc (MYL)

Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.

As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).

Generics Segment

The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.

The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.

In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.

In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.

Specialty Segment

The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.

Advisors' Opinion:

• [By Ben Levisohn]

  That decision has helped make Allergan the top performing pharmaceutical stock in the S&P 500. Its shares have gained 4.3% to $108.18, today at 2:32 p.m., besting Merck’s (MRK) 1.2% rise to $49.36, Mylan’s (MYL) 1.1% advance to $42.98, Hospira’s (HSP) 0.7% increase to $41.34 and Eli Lily’s (LLY) 0.6% rise to $50.42.

• [By Ben Levisohn]

  Mylan (MYL) has dropped 0.9% to $47.50 after the generic-drug maker missed analyst earnings forecasts and lowered the top end of its revenue and profit guidance.

• [By Ben Levisohn]

  Monday has been among the worst days for stocks this year, and today was no exception, as Pfizer (PFE), American Express (AXP), Valero Energy (VLO), Fossil Group (FOSL) and Mylan (MYL) tumbled.

Best Net Payout Yield Companies To Own For 2014: Philippine Long Distance Telephone Company(PHI)

Philippine Long Distance Telephone Company provides telecommunication services in the Philippines. Its Wireless segment offers cellular mobile services; Internet broadband distribution and services; call center services; mobile applications development and services; software development and sale of maintenance and support services; mobile commerce solutions; mobile commerce platforms; mobile applications development and services; solutions and systems integration services; satellite communications services; and satellite information and messaging services. This segment also involves in the promotion of the sale and/or patronage of debit and/or charge cards; offshore financing and risk management activities for smart; international trade of satellites and global system for mobile communication, or GSM enabled global telecommunications; and delivery of GSM communication capability for the maritime sector, as well as operates as a content provider. The company?s Fixed Line s egment provides fixed line telecommunication services, such as local exchange, international long distance, national long distance, data and other network services, as well as infrastructure and related services. Its Information and Communications Technology segment offers integrated information and communications technology services focusing on infrastructure and solutions for Internet applications, Internet protocol based solutions, and multimedia content delivery. This segment also provides knowledge processing solutions, customer relationship management, Internet and online gaming services, and information technology consulting and professional services; and operates Internet data center under the Vitro brand name. As of December 31, 2010, the company had served approximately 49 million subscribers. It also resells software licenses, server solutions, networking products, storage products, and data security products. The company was founded in 1928 and is based in Makati City, the Philippines.

Advisors' Opinion:

• [By Jonathan Yates]

  The economy is also expected to recover quickly from the storm's devastation, making Philippine Long Distance Telephone Company (NYSE: PHI) more attractive to long-term investors than other communications firms such as BCE (NYSE: BCE), AT&T (NYSE: T) and Verizon Communications (NYSE: VZ).

• [By David Dittman]

  Question: What are your thoughts on Exelon Corp�� (NYSE: EXC) buyout of Pepco Holdings Inc (NYSE: PHI)?

  Answer: It’s going to expand Exelon’s regulated operations, which is a good thing. And Pepco Holdings has been executing on a turnaround plan, with regulatory relations much improved.

• [By Ben Levisohn]

  The mixed signals were apparent even among the S&P 500′s best performing stocks, including� Exelon (EXC), a utility that’s nearing completion of a merger with Pepco Holdings (PHI), and Priceline (PCLN), a high-flying internet stock that rose, well, because it could. Exelon gained 7.9% to $36.83 this week, while Priceline rose 6.8% to $1,278.63.

Best Net Payout Yield Companies To Own For 2014: Brookfield Residential Properties Inc (BRP)

Brookfield Residential Properties Inc. (Brookfield Residential) is a land developer and homebuilder.The Company entitles and develops land and builds homes for its own communities, as well as sells lots to third-party builders. It operates in three segments in North America: Canada, California and Central and Eastern U.S. Each of the Company�� segments specializes in lot entitlement and development and the construction of single-family and multi-family homes. As of December 31, 2011, Brookfield Residential controlled 108,197 lots. The Company became a public company on March 31, 2011, by combining the former business of Brookfield Homes Corporation (Brookfield Homes) and the residential land and housing division (BPO Residential) of Brookfield Office Properties Inc. into a single residential land and housing company, achieved through a merger and series of related transactions completed on March 31, 2011. Advisors' Opinion:

• [By Ben Levisohn]

  In terms of specific company upside/downside payoffs, we believe that [Brookfield Residential Properties (BRP)], [KB Home], and [PulteGroup] offer above-average payoffs. We note that more than half of [Brookfield Residential Properties'] earnings are derived from Canada, dampening EPS sensitivity to our assumptions regarding the pace of the U.S. housing recovery. We believe that [KB Home] will achieve sharply improved operating performance, which should drive robust EPS growth given the company�� comparatively high degree of financial leverage. We also have a high degree of confidence that�[PulteGroup] will continue to successfully execute against its goal of improving ROIC performance, which should act as a catalyst for share price appreciation.